全球微量残存疾病检测市场规模、份额、趋势和成长分析报告（2026-2034年）

预计到 2034 年，微量残存疾病)检测市场规模将从 2025 年的 33.4 亿美元成长至 81 亿美元，2026 年至 2034 年的复合年增长率为 10.33%。

由于癌症发生率上升以及对先进诊断技术的需求，全球微量残存疾病（MRD）检测市场正在成长。 MRD检测有助于检测治疗后残留的少量癌细胞，从而促进患者后续观察并改善治疗效果。医疗机构越来越多地采用这些检测方法来评估治疗效果并降低復发风险。分子诊断技术的进步是推动市场成长的重要因素。

推动市场成长的主要因素包括对个人化医疗日益增长的需求以及癌症治疗策略的改进。次世代定序和流式细胞技术技术的进步提高了检测的准确性和灵敏度。医疗保健支出的增加和人们对疾病早期检测意识提升也促进了市场扩张。製药公司正在临床试验中使用微小残留病灶（MRD）检测，这进一步加速了其在研究和医疗机构中的应用。

在精准医疗领域不断创新的背景下，市场前景依然强劲。血液肿瘤和固态肿瘤研究的拓展将创造更多机会。在新兴市场，医疗基础设施的改善可望加速先进诊断工具的普及应用。在持续的技术进步和对早期检测日益重视的推动下，全球微量残存疾病）检测市场预计将在未来几年保持持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球微量残存疾病）检测市场：依技术划分

• 市场分析、洞察与预测
• 流式细胞技术（聚合酵素链锁反应（PCR）、次世代定序（NGS））
• 其他的

第五章：全球微量残存疾病检测市场：依癌症类型划分

• 市场分析、洞察与预测
• 骨髓恶性肿瘤
• 白血病
• 淋巴瘤
• 固态肿瘤

第六章：全球微量残存疾病检测市场：依最终用途划分

• 市场分析、洞察与预测
• 医院和专科诊所
• 诊断检查室
• 学术研究机构
• 其他的

第七章 全球微量残存疾病检测市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Exact Sciences Corporation
  • GRAIL LLC
  • Veracyte Inc
  • Natera Inc
  • Guardant Health
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine Inc
  • Qiagen
  • Mdxhealth
  • Bio-Techne

The Minimal Residual Disease Testing Market size is expected to reach USD 8.10 Billion in 2034 from USD 3.34 Billion (2025) growing at a CAGR of 10.33% during 2026-2034.

The Global Minimal Residual Disease Testing Market is growing due to the rising incidence of cancer and the need for advanced diagnostic techniques. Minimal residual disease (MRD) testing helps detect small amounts of cancer cells that remain after treatment, improving patient monitoring and outcomes. Healthcare providers are increasingly adopting these tests to assess treatment effectiveness and reduce relapse risks. Technological advancements in molecular diagnostics are significantly contributing to market growth.

Key drivers include the growing demand for personalized medicine and improved cancer management strategies. Advances in next-generation sequencing and flow cytometry technologies have enhanced test accuracy and sensitivity. Increased healthcare spending and awareness about early disease detection are also supporting market expansion. Pharmaceutical companies are using MRD testing in clinical trials, further driving adoption across research and medical institutions.

Future prospects for the market remain strong as innovation continues in precision medicine. Expanding research in hematological cancers and solid tumors will create additional opportunities. Emerging economies are expected to adopt advanced diagnostic tools as healthcare infrastructure improves. With continuous technological progress and growing focus on early detection, the Global Minimal Residual Disease Testing Market is projected to witness sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Flow Cytometry (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS))
• Others

By Cancer Type

• Hematological Malignancy
• Leukemia
• Lymphoma
• Solid Tumors

By End Use

• Hospitals and Specialty Clinics
• Diagnostic Laboratories
• Academic and Research Institutes
• Others

COMPANIES PROFILED

• Exact Sciences Corporation, GRAIL LLC, Veracyte Inc, Natera Inc, Guardant Health, F HoffmannLa Roche Ltd, Foundation Medicine Inc, Qiagen, mdxhealth, BioTechne
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Flow Cytometry (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Hematological Malignancy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Solid Tumors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals and Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology
  • 7.2.2 By Cancer Type
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology
  • 7.3.2 By Cancer Type
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology
  • 7.4.2 By Cancer Type
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology
  • 7.5.2 By Cancer Type
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology
  • 7.6.2 By Cancer Type
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MINIMAL RESIDUAL DISEASE TESTING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Exact Sciences Corporation
  • 9.2.2 GRAIL LLC
  • 9.2.3 Veracyte Inc
  • 9.2.4 Natera Inc
  • 9.2.5 Guardant Health
  • 9.2.6 F. Hoffmann-La Roche Ltd
  • 9.2.7 Foundation Medicine Inc
  • 9.2.8 Qiagen
  • 9.2.9 Mdxhealth
  • 9.2.10 Bio-Techne